Access to diagnostic tests and essential medicines for cardiovascular diseases and diabetes care: Cost, availability and affordability in the west region of Cameroon

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Jingi, Ahmadou M ^a   Noubiap, Jean Jacques N ^b   Onana, Arnold Ewane ^c   Nansseu, Jobert Richie N ^d   Wang, Binhuan ^e   Kingue, Samuel ^a   Kengne, André Pascal ^f  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b Internal Medicine Unit   (Cameroon)

^c YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

^d Department of Paediatrics   (Cameroon)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Non communicable Disease Research Unit   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; BENZATHINE PENICILLIN; CAPTOPRIL; CARDIOVASCULAR AGENT; ESSENTIAL DRUG; FUROSEMIDE; GENERIC DRUG; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPHANE INSULIN; ISOSORBIDE DINITRATE; LOSARTAN; METFORMIN; METHYLDOPA; NEUTRAL INSULIN; NIFEDIPINE; PHENOXYMETHYLPENINCILLINE; POTASSIUM; PROPRANOLOL; RAMIPRIL; SIMVASTATIN; SPIRONOLACTONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIDIABETIC AGENT;

AFFORDABILITY; ARTICLE; BLOOD CELL COUNT; CAMEROON; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES CARE; DIABETES MELLITUS; DIAGNOSTIC TEST; DRUG COST; DRUG QUALITY; ELECTROCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE CONCEPTS; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; ISCHEMIC HEART DISEASE; PATIENT CARE; POTASSIUM BLOOD LEVEL; PRIMARY PREVENTION; PROTEIN URINE LEVEL; RURAL AREA; SALARY; SECONDARY PREVENTION; TRIACYLGLYCEROL BLOOD LEVEL; URBAN AREA; UREA BLOOD LEVEL; CARDIOVASCULAR DISEASES; ECONOMICS; HEALTH CARE DELIVERY; POVERTY;

CAMEROON; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIAGNOSTIC TESTS, ROUTINE; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYPOGLYCEMIC AGENTS; POVERTY;

EID: 84940116319     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111812     Document Type: Article

References (34)

1. World Health Organization (2010) Global Status Report on Non-communicable Diseases 2010. Geneva: World Health Organization.
2. Abegunde D, Mathers CD, Adam T, Ortegon M, Strong K (2007). The burden and costs of chronic diseases in low-income and middle income countries. Lancet 370: 1929-38.
3. Joshi R, Jan S, Wu Y, MacMahon S (2008) Global inequalities in access to cardiovascular health care: our greatest challenge. J Am Coll Cardiol 52(23): 1817-25.
4. Kankeu HT, Saksena P, Xu K, Evans DB (2013) The financial burden from non-communicable diseases in low- And middle-income countries: A literature review. Health Res Policy Syst 11: 31.
5. Kengne AP, June-Rose McHiza, Amoah AG, Mbanya JC (2013) Cardiovascular diseases and diabetes as economic and developmental challenges in Africa. Prog Cardiovasc Dis 56(3): 302-13.
6. World Health Organization (2013) Prevention of recurrent heart attacks and strokes in low- And middle-income populations: Evidence based recommendations for policy makers and health professionals. Geneva: World Health Organization.
7. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr et al. (2007) The availability and affordability of selected essential medicines for chronic diseases in six low and middle-income countries. Bull World Health Organ 85: 279-88.
8. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R (2009) Medicine prices, availability, and affordability in 36 developing and middle income countries: A secondary analysis. Lancet 373 (9659): 240-9.
9. World Health Organization (2004) Equitable access to essential medicines: A framework for collective action. WHO Policy Perspectives on Medicines nu 8. Geneva: World Health Organization.
10. Ministère de la Santé Publique du Cameroun (2006) Plan stratégique pour la promotion et le développement des mutuelles de santé au Cameroun.
11. Noubiap JJ, Joko WY, Obama JM, Bigna JJ (2013) Community-based health insurance knowledge, concern, preferences, and financial planning for health care among informal sector workers in a health district of Douala, Cameroon. Pan Afr Med J 16: 17.
12. World Health Organization (2011) Global Health Observatory Data Repository. Health financing: health expenditure ratios by country. Available: http://apps.who.int/gho/data/node.main.75?lang=en. Accessed April 10, 2014.
13. Echouffo-Tcheugui JB, Kengne AP (2011) Chronic non-communicable diseases in Cameroon - burden, determinants and current policies. Global Health 7: 44.
14. Njamnshi A, Hiag AB, Mbanya JC (2006) From research to policy: The development of a national diabetes programme in Cameroon. Diabetes Voice 51(3): 18-21.
15. World Health Organization, Health Action International (2008) Measuring medicine prices, availability, affordability and price components 2nd edition. Available: http://www.haiweb.org/medicineprices/surveys.php. Accessed 04 April 2014.
16. eme recensement general de la population humaine (2010) La population du Cameroun en 2010. Available: http://www.statistics-cameroon.org/downloads/La-population-du-Cameroun-2010.pdf. Accessed April 4, 2014.
17. World Health Organization (2007) AFRO Essential medicines price indicator: WHO model list, 2007 edition.
18. World Health Organization (2007) Prevention of cardiovascular disease. Pocket guidelines for assessment and management of cardiovascular risk. Available: http://www.who.int/cardiovascular-diseases/guidelines/PocketGL.ENGLISH.AFR-D-E.rev1.pdf. Accessed 04 April 2014.
19. Gelders S, Ewen M, Noguchi N, Laing R (2006) Price, availability and affordability. An international comparison of chronic disease medicines. Cairo: World health Organization and Health Acton International; 2006. Available: http://www.haiweb.org/GlobalDatabase/Main.htm. Accessed 12 April 2014.
20. Management Sciences for Health (2012) International Drug Price Indicator Guide. Available: http://erc.msh.org/dmpguide/pdf/DrugPriceGuide-2012-en.pdf. Accessed 12 April 2014.
21. Mendis S, Al Bashir I, Dissanayake L, Varghese C, Fadhil I et al. (2012) Gaps in capacity in primary care in low-resource settings for implementation of essential non communicable disease interventions. Int J Hypertens 2012: 584041.
22. Kishore SP, Vendanthan R, Fuster V (2011) Promoting global cardiovascular health ensuring access to essential cardiovascular medicines in low- And middleincome countries. J Am Coll Cardiol 57(20): 1980-7.
23. Hogerzeil HV, Liberman J, Wirtz VJ, Kishore SP, Sevaraj S et al. (2013) Promotion of access to essential medicines for non-communicable diseases: Practical implications of the UN political declaration. Lancet 381(9867): 680-9.
24. Peck R, Mghamba J, Vanobberghen F, Kavishe B, Rugarabamu V et al. (2014) Preparedness of Tanzanian health facilities for outpatient primary care of hypertension and diabetes: A cross-sectional survey. Lancet Glob Health. published online April 14. http://dx.doi.org/10.1016/S2214-109X(14)70033-6.
25. Barrington J, Wereko-Brobby O, Ward P, Mwafongo W, Kungulwe S (2010) SMS for Life: A pilot project to improve anti-malaria drug supply management in rural Tanzania using standard technology. Malar J 9: 298.
26. Jiang M, Yang S, Yan K, Liu J, Zhao J et al. (2013) Measuring Access to Medicines: A Survey of Prices, Availability and Affordability in Shaanxi Province of China. PLoS One 8(8): E70836.
27. Heeley E, Anderson CS, Huang Y, Jan S, Li Y et al. (2009) Role of health insurance in averting economic hardship in families after acute stroke in China. Stroke 40: 2149-2156.
28. Vialle-Valentin CE, Ross-Degnaan D, Ntaganira J, Wagner AK (2008) Medicines coverage and community-based health insurance in low-income countries. Health Res Policy Syst 6: 11.
29. Quick JD (2003) Ensuring access to essential medicines in the developing countries: A framework for action. Clin Pharmacol Ther 73(4): 279-283.
30. Kanavos P, Costa-Font J, Seeley E (2008) Competition in off-patent drug markets: Issues regulation and evidence. Economic Policy 23: 499-544.
31. Joncheere K, Rietveld AH, Huttin C (2002) Experiences with generics. In Drugs and Money.7th edition. Edited by Dukes FM, Haaijer-Ruskamp CP, Joncheere A, Rietveld H. The Netherlands: Published on behalf of WHO-Europe: 101- 110. IOS Press.
32. World Health Organization (2010) The world health report-health systems fi nancing: The path to universal coverage. Geneva: World Health Organization.
33. Twagirumukiza M, Cosijns A, Pringels E, Remon J, Vervaet C et al. (2009) Influence of tropical climate conditions on the quality of antihypertensive drugs from Rwandan pharmacies. Am J Trop Med Hyg 81: 776-781.
34. Kotwani A (2013) Where are we now: Assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all. BMC Health Serv Res 13: 285.